Roche says Avastin combination treatment prolongs lung-cancer survival
Roche Holding AG said cancer drug Avastin in combination with chemotherapy met its primary endpoint of improving progression free survival in patients with previously untreated advanced non-small cell lung cancer (NSCLC) in a new Phase III study.
This entry was posted on Thursday, February 22nd, 2007 at 10:10 am and is filed under Research, Treatment. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.